No Clinical Impact of CYP3A5 Gene Polymorphisms on the Pharmacokinetics and/or Efficacy of Maraviroc in Healthy Volunteers and HIV‐1–Infected Subjects

Maraviroc is a C‐C chemokine receptor type‐5 antagonist approved for the treatment of HIV‐1. Previous studies show that cytochrome P450 3A5 (CYP3A5) plays a role in maraviroc metabolism. CYP3A5 is subject to a genetic polymorphism. The presence of 2 functional alleles (CYP3A5*1/*1) confers the exten...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:J Clin Pharmacol
Main Authors: Vourvahis, Manoli, McFadyen, Lynn, Nepal, Sunil, Valluri, Srinivas Rao, Fang, Annie, Fate, Gwendolyn D., Wood, Linda S., Marshall, Jean‐Claude, Chan, Phylinda L. S., Nedderman, Angus, Haynes, Julian, Savage, Mark E., Clark, Andrew, Smith, Kimberly Y., Heera, Jayvant
Format: Artigo
Sprog:Inglês
Udgivet: John Wiley and Sons Inc. 2018
Fag:
Pharmacogenomics
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6586010/
https://ncbi.nlm.nih.gov/pubmed/30192390
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.1306
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker